LP002
/ Lepu Med
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 28, 2022
Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: A prospective, open-label, phase Ib trial.
(ASCO 2022)
- P1 | "LP002 plus cisplatin and 5-fluorouracil was safe in pts with resectable gastric or GEJ cancer, and could be a new perioperative treatment option for PD-L1 positive disease. Pts are followed-up for survival outcomes."
Clinical • IO biomarker • P1 data • Anorexia • Endocrine Cancer • Endocrine Disorders • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Neuroendocrine Tumor • Oncology • Solid Tumor
February 16, 2021
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
(clinicaltrials.gov)
- P1; N=63; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.
Clinical • New P1 trial • Immune Modulation • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • PD-L1
February 05, 2021
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
(clinicaltrials.gov)
- P2; N=46; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.
Clinical • Combination therapy • New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
February 16, 2021
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
(clinicaltrials.gov)
- P1; N=94; Recruiting; Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd.
Clinical • New P1 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-L1
1 to 4
Of
4
Go to page
1